keyword
https://read.qxmd.com/read/37763057/danazol-as-a-treatment-for-uterine-arteriovenous-malformation-a-case-report
#21
Hyunjin Tak, Kyong-No Lee, Ji-Won Ryu, Keun-Young Lee, Ga-Hyun Son
Uterine arteriovenous malformation (AVM) is associated with a risk of massive uterine bleeding. Although uterine artery embolization remains the first-line treatment for AVM, there has been a recent exploration of pharmacological options. Danazol is known to reduce blood flow to the uterus; however, our understanding of its therapeutic efficacy for AVM remains limited. Herein, we present the results of danazol use in patients with uterine AVM. We retrospectively reviewed the medical records of patients who received danazol for the treatment of AVM between January 2013 and November 2022...
August 23, 2023: Journal of Personalized Medicine
https://read.qxmd.com/read/37761706/characteristics-and-drug-utilization-of-patients-with-hereditary-angioedema-in-italy-a-real-world-analysis
#22
JOURNAL ARTICLE
Elisa Giacomini, Melania Leogrande, Valentina Perrone, Margherita Andretta, Marcello Bacca, Alessandro Chinellato, Andrea Ciaccia, Mariarosaria Cillo, Renato Lombardi, Daniela Mancini, Romina Pagliaro, Maurizio Pastorello, Cataldo Procacci, Luca Degli Esposti
This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II and, III, were included). The index date was that of first prescription of HAE treatments within the inclusion period (01/2010-06/2021) or of the date of exemption. The number of HAE patients included was 148 (43...
September 10, 2023: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/37753281/no-effect-of-danazol-treatment-in-patients-with-advanced-idiopathic-pulmonary-fibrosis
#23
JOURNAL ARTICLE
Thijs W Hoffman, Coline H M van Moorsel, Joanne J van der Vis, Douwe H Biesma, Jan C Grutters
BACKGROUND: Telomere dysfunction can underly the development of idiopathic pulmonary fibrosis (IPF), and recent work suggests that patients with telomere syndromes might benefit from treatment with androgens, such as danazol. METHODS: This was a prospective observational cohort study. 50 patients with IPF received off-label treatment with danazol after they showed progressive disease under treatment with pirfenidone or nintedanib. The primary outcome was the difference in yearly decline in forced vital capacity (FVC) prior to (pre) and after (post) start of treatment with danazol...
September 2023: ERJ Open Research
https://read.qxmd.com/read/37727628/real-world-experience-of-hereditary-angioedema-hae-in-mexico-a-mixed-methods-approach-to-describe-epidemiology-diagnosis-and-treatment-patterns
#24
JOURNAL ARTICLE
Sandra Nieto, Ileana Madrigal, Francisco Contreras, María Eugenia Vargas
INTRODUCTION AND OBJECTIVES: Due to the lack of structured and systematic information available, the aim of this study was to describe the epidemiology, diagnosis, healthcare processes, and treatment patterns of hereditary angioedema (HAE) in Mexico. To achieve this, different data sources were consulted regarding medical literature, structured health system databases, and angioedema-specialized physicians (AEP) opinion regarding HAE. MATERIAL AND METHODS: A mixed methods approach was conducted in 4 phases: I) systematic literature review (SLR) and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; II) review of national health system (NHS) databases and systematic reports; III) physician survey; and IV) an epidemiologic model...
September 2023: World Allergy Organization Journal
https://read.qxmd.com/read/37640546/danazol-increases-the-oral-bioavailability-of-midazolam-by-inactivation-of-hepatic-and-intestinal-cyp3a-in-rats
#25
JOURNAL ARTICLE
Shuhei Fukuno, Katsuhito Nagai, Akemi Kurotobi, Yuki Sahori, Ryo Nakagawa, Rena Nomura, Takuya Ito, Hiroki Konishi
1. Danazol (DNZ) is a synthetic androgen derivative used for the treatment of intractable hematological disorders. In this study, we investigated the effects of DNZ on CYP3A activity in hepatic and small intestinal microsomes and the pharmacokinetics of midazolam (MDZ), a typical substrate for CYP3A, in rats.2. MDZ 4-hydroxylation activities in hepatic and small intestinal microsomes significantly decreased 24 hours after DNZ (100 mg/kg, i.p.) treatment. Time-dependent inactivation of MDZ 4-hydroxylation activities was noted when microsomes were pre-incubated with DNZ in the presence of a NADPH-generating system...
August 28, 2023: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/37592101/gynecomastia
#26
REVIEW
Ahila Ayyavoo
Enlargement of breasts among boys is termed gynecomastia. This could be due to an alteration in the androgen-estrogen ratio along with the effects of other hormones including growth hormone, insulin like growth factor 1, prolactin, and other factors affecting aromatase enzyme. The common causes of gynecomastia are pubertal gynecomastia, obesity, drugs and hypogonadism. Several other diseases including liver or renal failure, thyrotoxicosis, Klinefelter syndrome, tumors and environmental pollutants can cause gynecomastia...
October 2023: Indian Journal of Pediatrics
https://read.qxmd.com/read/37577027/microbiota-dysbiosis-in-hereditary-angioedema-patients
#27
JOURNAL ARTICLE
Öner Özdemir
I have read the article titled " Throat microbiota alterations in patients with hereditary angioedema " by Wang et al (2022) with great interest. This study examined the change in throat microbiota and its association with laryngeal edema (LE) attacks and attack severity in hereditary angioedema (HAE) patients. This study demonstrated the comparative richness of Bacteroidetes and Prevotellaceae in recent LE attacks and detected positive association between the attack severity scores and Bacteroidetes richness...
August 2023: World Allergy Organization Journal
https://read.qxmd.com/read/37543781/efficacy-and-safety-of-different-subsequent-therapies-after-fertility-preserving-surgery-for-endometriosis-a-systematic-review-and-network-meta-analysis
#28
JOURNAL ARTICLE
Yu Zheng, Ruyue Ma, Hong Xu, Lian Wang, Lei Zhang, Huiqun Mao, Ruiheng Zhao
BACKGROUND: Endometriosis (EMT) is a benign and common estrogen-dependent disease. Hormonal therapy improves pain symptoms in most women with EMT. However, in many cases, laparoscopic fertility preservation surgery is considered a common treatment for EMT. The present study aimed to evaluate the efficacy and safety of dienogest, leuprolide, danazol, gestrinone, mifepristone and levonorgestrel intrauterine system (LNG-IUS) in relieving symptoms and delaying the recurrence of EMT cysts after fertility protection surgery...
August 4, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/37517413/momelotinib-versus-danazol-in-symptomatic-patients-with-anaemia-and-myelofibrosis-previously-treated-with-a-jak-inhibitor-momentum-an-updated-analysis-of-an-international-double-blind-randomised-phase-3-study
#29
JOURNAL ARTICLE
Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N Harrison, Stephen Oh, Barbara J Klencke, Jing Yu, Rafe Donahue, Jun Kawashima, Ruben Mesa
BACKGROUND: The MOMENTUM study met all key endpoints at week 24, demonstrating symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis. In this updated analysis, we report duration of week 24 responses and new responses with momelotinib through week 48. METHODS: MOMENTUM is an international, double-blind, randomised, phase 3 study done at 107 sites across 21 countries. Patients were 18 years or older with primary, post-polycythaemia vera, or post-essential thrombocythaemia myelofibrosis, previously treated with an approved Janus kinase (JAK) inhibitor for 90 days or more (≥28 days with haematological complications), and had an Eastern Cooperative Oncology Group performance status of 2 or less...
July 27, 2023: Lancet Haematology
https://read.qxmd.com/read/37476605/a-randomized-controlled-intervention-trial-with-danazol-to-improve-telomeric-and-fertility-parameters-in-women-with-diminished-ovarian-reserve-a-pilot-study
#30
JOURNAL ARTICLE
Isabel Córdova-Oriz, Graciela Kohls, Carlos Iglesias, Alba M Polonio, Lucía Chico-Sordo, Mónica Toribio, Marcos Meseguer, Elisa Varela, Antonio Pellicer, Juan A García-Velasco
BACKGROUND: Most women who are treated at in vitro fertilization (IVF) clinics have trouble conceiving due to ovarian failure (OF), which seems to be associated to short telomeres and reduced or absent telomerase activity in their granulosa cells. Indeed, telomere pathways are involved in organ dysfunction. However, sexual steroids can stimulate the expression of the telomerase gene and have been successfully used to prevent telomere attrition. Thus, a strategy to improve IVF outcomes in women with OF could be telomerase reactivation using sexual steroids...
2023: Women's health reports
https://read.qxmd.com/read/37388810/management-of-hereditary-angioedema-in-resource-constrained-settings-a-consensus-statement-from-indian-subcontinent
#31
JOURNAL ARTICLE
Ankur Kumar Jindal, Archan Sil, Ridhima Aggarwal, Keshavamurthy Vinay, Anuradha Bishnoi, Deepti Suri, Amit Rawat, Muthu Sendhil Kumaran, Biman Saikia, Rashmi Sarkar, Lalit Gupta, D Dinesh Kumar, Rashmi Jindal, T U Sukumaran, Jose Ouseph, Hilary Longhurst, Ruby Pawankar, Surjit Singh, Sunil Dogra
Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i...
June 2023: Asia Pacific Allergy
https://read.qxmd.com/read/37352668/gastrointestinal-bleeding-in-patients-supported-with-left-ventricular-assist-devices-the-journey-from-bridging-to-destination
#32
REVIEW
Mohamed Salah Mohamed, Ahmed Shehadah, Anas Hashem, Swati Chand, Jay Bapaye, Amani Khalouf, Devesh Rai, Shajan Peter
End-stage heart failure is a prevalent and fatal cardiovascular disease. Almost 1 in 4 cases of mortality in the United States is attributed to heart failure. Left ventricular assist devices (LVADs) have emerged as a safe destination therapy or bridge to transplant. Despite remarkable results, LVAD is associated with significant adverse events, such as gastrointestinal bleeding (GIB). In this review, we aimed to understand the incidence and prevalence, pathophysiologic mechanisms, predictors, diagnostic mechanisms, management, and preventative measures of GIB in patients with an LVAD...
June 21, 2023: American Journal of Cardiology
https://read.qxmd.com/read/37341141/gonadotropin-releasing-hormone-analogues-for-endometriosis
#33
REVIEW
Veerle B Veth, Majorie Ma van de Kar, James Mn Duffy, Madelon van Wely, Velja Mijatovic, Jacques Wm Maas
BACKGROUND: Endometriosis is a common gynaecological condition affecting 6 to 11% of reproductive-age women and may cause dyspareunia, dysmenorrhoea, and infertility. One treatment strategy is medical therapy with gonadotrophin-releasing hormone analogues (GnRHas) to reduce pain due to endometriosis. One of the adverse effects of GnRHas is a decreased bone mineral density. In addition to assessing the effect on pain, quality of life, most troublesome symptom and patients' satisfaction, the current review also evaluated the effect on bone mineral density and risk of adverse effects in women with endometriosis who use GnRHas versus other treatment options...
June 21, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/37318468/temporal-relationship-between-thromboembolic-events-and-myeloproliferative-neoplasm-diagnosis-is-it-associated-with-mortality-risk
#34
JOURNAL ARTICLE
E Gulturk, D Yılmaz, G Bırce Sonmezoz, M Dırıl
OBJECTIVE: The aim of this study is to investigate the temporal relationship between the first occurrence of thromboembolic events (TEE) and the timing of myeloproliferative neoplasm (MPN) diagnosis and to determine risk factors for TEE-related mortality in MPN. PATIENTS AND METHODS: A total of 138 BCR-ABL-negative MPN patients with TEE, diagnosed from January 2010 to December 2019, were included in this retrospective cohort. Patients were compared according to mortality and subjects were classified into three groups with respect to having suffered index TEE before, during, or after MPN diagnosis...
June 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37248521/a-multicenter-chart-review-of-patient-characteristics-treatment-and-outcomes-in-hereditary-angioedema-unmet-need-for-more-effective-long-term-prophylaxis
#35
JOURNAL ARTICLE
Joan Mendivil, Maral DerSarkissian, Aleena Banerji, Lavanya Diwakar, Constance H Katelaris, Paul K Keith, Harold Kim, Gina Lacuesta, Markus Magerl, Charlotte Slade, William B Smith, Zia Choudhry, Angela Simon, Sujata P Sarda, Paula J Busse
BACKGROUND: Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, recurring subcutaneous or submucosal swelling. Without effective therapy, HAE can negatively impact patients' quality of life. Management of HAE includes on-demand treatment of attacks and short- and long-term prophylaxis (LTP) to prevent attacks. Newer therapies may be more tolerable and effective in managing HAE; however, therapies such as androgens are still widely used in some countries owing to their relative ease of access and adequate disease control for some patients...
May 29, 2023: Allergy, Asthma, and Clinical Immunology
https://read.qxmd.com/read/37223763/gnrh-agonists-in-the-treatment-of-symptomatic-endometriosis-a-review
#36
JOURNAL ARTICLE
Eric S Surrey
The development of highly potent gonadotropin-releasing hormone agonists (GnRHa) allowed for a significant addition to options for the medical management of symptomatic endometriosis. Pituitary GnRH receptor down-regulation leads to a hypogonadotropic and secondary hypoestrogenic state resulting in lesion regression and symptom improvement. There may be an additional effect of these agents on the inflammatory processes associated with endometriosis as well. This is a review of critical milestones in the clinical application of these agents...
June 2023: F&S reports
https://read.qxmd.com/read/37146882/a-national-survey-of-hereditary-angioedema-and-acquired-c1-inhibitor-deficiency-in-the-united-kingdom
#37
JOURNAL ARTICLE
Patrick Fk Yong, Tanya Coulter, Tariq El-Shanwany, Tomaz Garcez, Scott Hackett, Rashmi Jain, Sorena Kiani-Alikhan, Ania Manson, Sadia Noorani, Catherine Stroud, Christine Symons, Ravishankar Sargur, Cathal Steele, Hana Alachkar, Ariharan Anantharachagan, Peter D Arkwright, Jolanta Bernatoniene, Malini Bhole, Lindsay Brown, Matthew Buckland, Siobhan Burns, Charu Chopra, James Darroch, Elizabeth Drewe, Jillian Edmonds, Anjali Ekbote, Shuayb Elkhalifa, Sarah Goddard, Dorothea Grosse-Kreul, Padmalal Gurugama, Rosie Hague, Richard Herriot, Archana Herwadkar, Stephen M Hughes, Laura Jones, Sara Lear, Elizabeth McDermott, Sai Hurng Kham Murng, Arthur Price, Vyanka Redenbaugh, Alex Richter, Andrew Riordan, Fiona Shackley, Julia Stichbury, Debbie Springett, Michael D Tarzi, Moira Thomas, Pavaladurai Vijayadurai, Austen Worth
BACKGROUND: Detailed demographic data on people with hereditary angioedema and acquired C1 inhibitor deficiency in the UK are relatively limited. Better demographic data would be beneficial in planning service provision, identifying areas of improvement and improving care. OBJECTIVE: To obtain more accurate data on the demographics of hereditary angioedema and acquired C1 inhibitor deficiency in the UK, including treatment modalities and services available to patients...
May 3, 2023: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/37122983/gonadotropin-releasing-hormone-gnrh-gnrh-receptors-and-their-role-in-the-treatment-of-endometriosis
#38
REVIEW
Christina Resta, Athanasios Moustogiannis, Eirini Chatzinikita, Dimitris Malligiannis Ntalianis, Konstantinos Malligiannis Ntalianis, Anastasios Philippou, Michael Koutsilieris, Nikolaos Vlahos
Endometriosis, defined as the development of endometrial tissue outside of the uterine cavity, is a common gynecological disorder. The prevalence of pelvic endometriosis approaches 6%-10% in the general female population, and in women with pain, infertility, or both, the frequency is 35%-50%. The gold standard recommended process for diagnosing endometriosis is laparoscopy, an invasive surgical procedure, with or without histologic verification. The currently available nonsurgical treatments include oral contraceptives (estrogen-progestogen preparations), progestogen preparations (containing progesterone derivatives), androgenic hormones (danazol), and gonadotropin-releasing hormone (GnRH) agonists and antagonists...
April 2023: Curēus
https://read.qxmd.com/read/37042865/momelotinib-long-term-safety-and-survival-in-myelofibrosis-integrated-analysis-of-phase-3-randomized-controlled-trials
#39
JOURNAL ARTICLE
Srdan Verstovsek, Ruben A Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T Oh, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire N Harrison
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis. This long-term analysis pooled data from 3 randomized phase 3 studies of momelotinib (MOMENTUM, SIMPLIFY-1, SIMPLIFY-2), representing myelofibrosis disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages. Patients in the control arms (danazol in MOMENTUM; ruxolitinib in SIMPLIFY-1; best available therapy in SIMPLIFY-2) could cross over to receive momelotinib at the end of the 24-week randomized period, and all patients could continue momelotinib treatment after the completion of these studies via an extended access protocol...
April 12, 2023: Blood Advances
https://read.qxmd.com/read/36999006/danazol-treatment-for-thrombocytopenia-in-myelodysplastic-syndromes-can-an-old-fashioned-drug-be-effective
#40
JOURNAL ARTICLE
Marta Riva, Alessandro Bosi, Lorenzo Rizzo, Federico Mazzon, Silvia Ferrari, Federico Lussana, Lorenza Borin, Andrea Castelli, Roberto Cairoli, Wilma Barcellini, Alfredo Molteni, Bruno Fattizzo
No abstract text is available yet for this article.
April 2023: HemaSphere
keyword
keyword
104639
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.